Despite positive clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial opposition from PBMs. The organizations are often creating barriers to access, including high expense requirements and prior authorization that limit user availability. Analysts indicate that s… Read More